Anti-eNOS 抗体 [EPR19296]
Anti-eNOS antibody [EPR19296]
- RabMAb
- Recombinant
- 了解详情
4
(3 Reviews)
|
(58 Publications)
Rabbit Recombinant Monoclonal eNOS antibody. Suitable for IP, WB and reacts with Human, Mouse, Rat samples. Cited in 58 publications.
查看别名
Nitric oxide synthase 3, Constitutive NOS, EC-NOS, NOS type III, cNOS, NOSIII, Endothelial NOS, eNOS, NOS3
- IP
Supplier Data
Immunoprecipitation - Anti-eNOS antibody [EPR19296] (AB199956)
eNOS was immunoprecipitated from 1 mg of HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with ab199956 at 1/50 dilution. Western blot was performed from the immunoprecipitate using ab199956 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1 : HepG2 whole cell lysate 10 μg (Input).
Lane 2 : ab199956 IP in HepG2 whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab199956 in HepG2 whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 seconds.
All lanes:
Immunoprecipitation - Anti-eNOS antibody [EPR19296] (ab199956)
Predicted band size: 133 kDa
false
- WB
Supplier Data
Western blot - Anti-eNOS antibody [EPR19296] (AB199956)
Blocking/Dilution buffer : 5% NFDM/TBST.
eNOS is shown to be expressed in platelets, placenta, liver and kidney (UniProt entry P29474). It also plays an important role in the cardiovascular system. (PMID : 15210449 & 15936740).
All lanes:
Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1:
Human fetal heart lysate at 20 µg
Lane 2:
Human fetal kidney lysate at 20 µg
Lane 3:
Human fetal liver lysate at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
false
Exposure time: 3min
- WB
Supplier Data
Western blot - Anti-eNOS antibody [EPR19296] (AB199956)
Blocking/Dilution buffer : 5% NFDM/TBST.
The expression profile observed is consistent with what has been described in the literature (PMID : 17855661 & 11004215).
All lanes:
Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/5000 dilution
Lane 1:
HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 20 µg
Lane 2:
Whole cell lysate from HepG2 cells treated with 10 μg/ml LPS for 2 hours at 20 µg
Lane 3:
Whole cell lysate from HepG2 cells treated with 10 μg/ml LPS for 6 hours at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
false
Exposure time: 15s
- WB
Lab
Western blot - Anti-eNOS antibody [EPR19296] (AB199956)
Exposure Time : Lane1 : 40 seconds; Lane2 : 180 seconds
The expression profile observed in HeLa is consistent with the literature (PMID : 19925457).
Negative control : HeLa (PMID : 19925457)
All lanes:
Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1:
HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
false
- WB
Supplier Data
Western blot - Anti-eNOS antibody [EPR19296] (AB199956)
Blocking/Dilution buffer : 5% NFDM/TBST.
Exposure time : Lane 1, 2, 3, 4, 6 and 7 : 30 seconds; Lane 5 : 2 minutes.
eNOS is shown to be expressed in platelets, placenta, liver and kidney (UniProt entry P29474). It also plays an important role in the cardiovascular system. (PMID : 15210449 & 15936740).
All lanes:
Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1:
Mouse brain lysate at 10 µg
Lane 2:
Mouse heart lysate at 10 µg
Lane 3:
Mouse kidney lysate at 10 µg
Lane 4:
Mouse spleen lysate at 10 µg
Lane 5:
Rat brain lysate at 10 µg
Lane 6:
Rat heart lysate at 10 µg
Lane 7:
Rat spleen lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
false
- WB
Supplier Data
Western blot - Anti-eNOS antibody [EPR19296] (AB199956)
Blocking/Dilution buffer : 5% NFDM/TBST.
Exposure time : Lane 1 : 1 second; Lane 2 : 3 minutes.
All lanes:
Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1:
Western blot - Recombinant Human eNOS protein (His-DDDDK tag N-Terminus) (<a href='/products/proteins-peptides/recombinant-human-enos-protein-tagged-ab198066'>ab198066</a>) at 0.01 µg
Lane 2:
Western blot - Recombinant Human iNOS protein (His-DDDDK tag N-Terminus) (<a href='/products/proteins-peptides/recombinant-human-inos-protein-ab135010'>ab135010</a>) at 0.05 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
false
不同偶联物与剂型 (1)
-
Anti-eNOS antibody [EPR19296] - BSA and Azide free
反应性数据
产品详情
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存时间
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ENOS contributes significantly to the regulation of vascular tone and blood flow by promoting vasodilation. It does not function alone; instead it forms complexes with other proteins to exert its full effect. eNOS activity influences the process of angiogenesis inflammation modulation and platelet aggregation. Through its ability to produce nitric oxide eNOS acts as a signaling molecule helping maintain vascular homeostasis.
Pathways
ENOS is a critical player in the NO signaling pathway and interacts intricately with the PI3K/Akt pathway. Nitric oxide produced by eNOS has a role in signaling cascades that lead to vascular dilation and reduced blood pressure. The PI3K/Akt pathway regulates eNOS activity via phosphorylation enhancing NO production. Other proteins like caveolin-1 and calmodulin modulate eNOS impacting these pathways' outcomes.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (58)
Recent publications for all applications. Explore the full list and refine your search
World journal of diabetes 16:109553 PubMed40980297
2025
Applications
Unspecified application
Species
Unspecified reactive species
Kidney & blood pressure research 50:442-459 PubMed40451155
2025
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 26: PubMed40332770
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of molecular histology 56:103 PubMed40063284
2025
Applications
Unspecified application
Species
Unspecified reactive species
Antioxidants (Basel, Switzerland) 13: PubMed39334728
2024
Applications
Unspecified application
Species
Unspecified reactive species
Investigative ophthalmology & visual science 65:34 PubMed39186263
2024
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 28:400 PubMed39171145
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of ophthalmology 2024:7195550 PubMed39049847
2024
Applications
Unspecified application
Species
Unspecified reactive species
Regenerative therapy 27:398-407 PubMed38694446
2024
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 27:183 PubMed38515647
2024
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com